uniQure N.V. (NASDAQ:QURE) Files An 8-K Other Events

uniQure N.V. (NASDAQ:QURE) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events

On January30, 2017, uniQure N.V. (the Company) issued a press
release announcing that the U.S. Food and Drug Administration
(FDA) has granted Breakthrough Therapy designation for AMT -060,
the Companys gene therapy in development for the treatment of
hemophilia B.

A copy of the press release is filed herewith as Exhibit99.1 and
is incorporated by reference herein in its entirety.

Item 9.01 Financial Statements and
Exhibits

(d)

Exhibits

99.1

Press release dated January30, 2017.


About uniQure N.V. (NASDAQ:QURE)

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson’s Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington’s disease, in which the Company has demonstrated preclinical proof of concept.

uniQure N.V. (NASDAQ:QURE) Recent Trading Information

uniQure N.V. (NASDAQ:QURE) closed its last trading session up +0.10 at 5.47 with 108,806 shares trading hands.

An ad to help with our costs